Ethan Allen Interiors Inc. will announce its financial and operational results for the first quarter of fiscal 2027, ending September 30, 2026, after market close on November 9, 2026. The company will hold a conference call at 5:00 p.m. Eastern Time to discuss these results, accessible via their Investor Relations website. This update is important for investors tracking the company's performance and growth plans.
Ethan Allen's upcoming fiscal 2027 first quarter results announcement is set for November 9, 2026. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Oct 19, 2026 15:11 WIB: out of 134 priced US stocks, 72 rose and 29 fell. Notable movers include Carvana Co (CVNA) at USD 59.56 with a 1-day change of +1.24% and a typical hold time on Pluang of 28 days, Norwegian Cruise Line Holdings Ltd (NCLH) at USD 15.23 with +1.20%, and Lennar Corporation (LEN) at USD 77.99 with +1.18%.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
